Clinical Trial

Tailoring Treatment in Colorectal Cancer

Study acronym: TargetCRC
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 6, 2024 (before its estimated March 28, 2025 completion). Its status may not reflect the trial's current state.
Summary
In this study, the investigators will establish a reliable method and logistic pipeline for personalized drug testing ex vivo using fresh tumor samples from colorectal cancer (CRC) patients. With this, the investigators aim to develop a novel predictive biomarker of immunotherapy response, by testing combinations of chemotherapies and chimeric antigen receptor (CAR) T cells. Critically, this affects a large subgroup of patients currently not considered to benefit from such treatment. To support the hypothesis, the project will make use of cutting-edge, cell-based functional diagnostics. Individual patients' cancer cells will be screened against a panel of chemotherapies and targeted therapies including CAR T cells, to assess the optimal combination of therapies to induce immunotherapy efficacy in otherwise unresponsive CRC.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-05-28; most recent amendment 2024-08-04.
Trial Details
NCT Number NCT05401318
Lead Sponsor University Hospital, Akershus
Collaborators: Oncosyne AS, Oslo University Hospital
Conditions Colorectal Neoplasms
Enrollment 40 participants
Start Date 2022-03-28
Primary Completion 2025-03-28 (estimated)
Study Completion 2027-01-01 (estimated)
Updated on ClinicalTrials.gov 2024-08-06